

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1, 2007

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-16133

06-1245881

(State or other jurisdiction of
incorporation)

Commission File
Number)

(IRS Employer
Identification No.)

1100 Summer Street, Stamford, Connecticut
(Address of principal executive offices)

06905
(Zip Code)

Registrant's telephone number, including area code: (203) 323-8668

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

2

Section 5 - Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a) Not applicable.

(b) Not applicable.

(c) Not applicable.

(d) Not applicable.

(e) At a meeting of the Compensation and Stock Option Committee of the Board of Directors of Delcath Systems, Inc. (the "Company") on February 1, 2007, the Committee approved an increase in the monthly compensation payable to Richard Taney, the Company's Chief Executive Officer, from \$20,000 to \$30,000.

(f) Not applicable.

Section 8- Other Events

Item 8.01 Other Events.

Appointment of Chairman

On February 2, 2007 the Company issued a press release announcing that Harold S. Koplewicz, M.D. had been appointed Chairman of the Company's Board of Directors at the meeting of the Board held on February 1, 2007.

Further information concerning Dr. Koplewicz is contained in the Company's press release dated February 2, 2007, a copy of which is filed as Exhibit 99 hereto and which is incorporated herein by reference.

Settlement of Litigation

In addition, the Company announced in its February 2, 2007 press release that it had settled its lawsuit against Jonathan A. Foltz, the Company's former Director of Operations. The settlement provides for mutual releases of claims and for the Company to pay a portion of Mr. Foltz's attorneys fees.

Filter Technology and Evaluation

On February 5, 2007 Delcath was informed of a voluntary commercial filter recall by its current filter manufacturer due to issues concerning sterility assurance. However, both because the Company's use of these filters is investigational rather than commercial and because the FDA approved protocols for the Company's clinical trials require filter sterilization at each study center as part of the procedure, the commercial recall will not prevent the Company from continuing its clinical trials currently in progress. In addition, in response to a request from the Food and Drug Administration and in an effort to further characterize the performance attributes of its current filters, Delcath had already begun a series of detailed testing protocols with a number of recognized filter testing laboratories. This comprehensive testing program will establish a more complete set of baseline empirical data for our current filters and provide the basis for comparative evaluations of new filters from alternative suppliers. The Company is taking a number of steps to assess its current filter and catheter technologies and has embarked on an active program of research and development with leading hemo-filtration technology companies. The objectives of this initiative are to improve and enlarge the Company's intellectual property position and to develop novel filter technologies to optimize performance and enable expanded clinical applications. The ongoing filter testing program will both support the continued use of the current filters in Delcath's clinical studies and provide a reference standard for the development and assessment of new filters and filtration technologies.

Section 9 - Financial Statements and Exhibits.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits:

Exhibit	Description
99	Press Release dated February 1, 2007 of Delcath Systems, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

By: /s/ RICHARD TANEY

Richard Taney
Chief Executive Officer

Date: February 7, 2007

EXHIBIT INDEX

Exhibit	Description
99	Press Release dated February 1, 2007 of Delcath Systems, Inc.

[GRAPHIC OMITTED]

Company Contact:
Delcath Systems, Inc.
Richard Taney
203-323-8668
www.delcath.com

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Worldwide
(212) 896-1215 / (212) 896-1250
tfromer@kcsa.com / grussell@kcsa.com

Media Contact:
Lewis Goldberg
KCSA Worldwide
(212) 896-1216
lgoldberg@kcsa.com

FOR IMMEDIATE RELEASE

Delcath Elects Dr. Harold Koplewicz
Chairman of the Board of Directors

Delcath Settles Litigation Against Former Director of Operations

STAMFORD, Conn., February 2, 2007 -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that Harold S. Koplewicz, M.D. was appointed Chairman of the Board of Directors at its meeting on Thursday, February 1, 2007. Dr. Koplewicz, 54, was initially appointed as an independent director of Delcath's Board in September 2006.

"I am honored that the Board has selected me to be Delcath Systems' new Chairman," stated Dr. Koplewicz. "Delcath has a fresh new outlook for moving forward and the Board is taking on a more aggressive strategy to advance the company." He added, "In earlier clinical trials, the Delcath system has shown tremendous potential as an effective therapy for inoperable liver cancer. Considering there is currently no effective therapy for inoperable liver cancer, where patients have an average life expectancy of less than nine months, there is an immediate real-world need for our technology and we need to move ahead with a greater sense of urgency."

Richard Taney, CEO of Delcath Systems, stated, "Since joining the Board, Harold has proven to be an excellent resource for Delcath. Through his association with some of the country's premier medical centers along with his established relationships with other leading medical professionals, Harold will help us in our effort to recruit additional sites for the Phase III Melphalan trial and explore additional applications for our intellectual property."

In addition, Delcath announced that it has settled its lawsuit against Mr. Jonathan Foltz, the former Director of Operations of Delcath. Mr. Taney stated, "The company is pleased that this matter has been satisfactorily resolved as we continue to refocus our energies on our primary mission of obtaining regulatory approval for the Delcath system."

About Harold S. Koplewicz, M.D.

Dr. Koplewicz was appointed by Governor George Pataki to the position of Executive Director of the Nathan S. Kline Institute for Psychiatric Research (NKI), one of only two research hospitals funded by New York State in May 2006. He is only the third person to hold this prestigious title since 1952. Dr. Koplewicz is also currently the Arnold and Debbie Simon Professor and Chairman of the Department of Child and Adolescent Psychiatry and Professor of Pediatrics and founder of the NYU Child Study Center at the New York University School of Medicine.

Castle Connolly Medical, an extensive survey of thousands of physicians each year, and New York Magazine have repeatedly named Dr. Koplewicz as one of America's Top Doctors. He is a nationally renowned child and adolescent psychiatrist, who regularly appears on national media, including The Today Show, National Public Radio, Good Morning America, LIVE with Regis and Kelly, Oprah, The View, CNN American Morning, CNN Weekend Housecalls, NBC Nightly News, ABC World News Tonight and Dateline NBC.

He has served as a member of the National Board of Medical Examiners and as a commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System.

About Delcath Systems, Inc.

Delcath Systems is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.

This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

#